# Nuclide record cabinet (trial). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/trials/cabinet/>
  a schema:MedicalTrial ;
  nuclide:kind "trial" ;
  schema:identifier "cabinet", "NCT03375320" ;
  schema:name "CABINET (Alliance A021602)"@en ;
  schema:description "Cabozantinib tripled the time without progression in neuroendocrine tumours that had outgrown other treatments, leading to a 2025 approval."@en ;
  schema:url <https://nuclide.cc/trials/cabinet/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03375320>, <https://businesswire.com/news/home/20251016096352/en/Exelixis-Announces-Results-from-Subgroup-Analysis-of-CABINET-Phase-3-Pivotal-Trial-Evaluating-CABOMETYX-cabozantinib-in-Advanced-Lung-and-Thymic-Neuroendocrine-Tumors-at-ESMO-2025> ;
  nuclide:status "positive" ;
  nuclide:phase "3" ;
  nuclide:indications <https://nuclide.cc/indications/neuroendocrine/>, <https://nuclide.cc/indications/pancreatic-net/>, <https://nuclide.cc/indications/small-intestinal-net/>, <https://nuclide.cc/indications/lung-net/> ;
  nuclide:drugs <https://nuclide.cc/drugs/cabozantinib/> .